Company Profile
Chemomab Therapeutics Stock Price, News & Catalysts
- Ticker:
- CMMB
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Israel
Stock performance
2.80 USD (+5.66%)
Close
Last updated: September 17, 2026
12.5M USD
Market cap
Why the stock is moving
As of Sep 17, 2026, CMMB closed up 5.66% at $2.80. No new same-company headline was identified in the current news window.
Company overview
Immune-Fibrotic Disease Company
Chemomab Therapeutics is a clinical-stage biotechnology company developing therapies for diseases driven by fibrosis and inflammation. Its research is centered on CCL24, a soluble signaling protein implicated in immune-cell recruitment, tissue remodeling, and fibrotic disease progression.
CCL24 Biology
CCL24 is believed to promote both inflammatory and fibrotic pathways, giving Chemomab a single target through which to address two interconnected components of immune-fibrotic disease. The company has built its therapeutic strategy around neutralizing CCL24 to alter the underlying biology rather than treating symptoms alone.
Nebokitug
Nebokitug is a first-in-class monoclonal antibody designed to bind and neutralize CCL24. The candidate has demonstrated a generally favorable safety and tolerability profile across clinical studies and is intended as a platform therapy for multiple severe immune-mediated and fibrotic conditions.
Primary Sclerosing Cholangitis Program
Chemomab evaluated nebokitug in the Phase 2 SPRING trial in primary sclerosing cholangitis, a chronic liver disease with no FDA-approved therapy. Biomarker analyses showed dose-dependent effects on inflammatory, immune, and tissue-remodeling signatures, including pathways relevant to patients with coexisting inflammatory bowel disease.
Precision-Medicine Expansion into Rheumatoid Arthritis
Scipher Medicine's SPECTRA AI-enabled network-medicine platform identified nebokitug as a highly ranked clinical candidate for rheumatoid arthritis. Chemomab and Scipher plan to combine nebokitug with a molecular treatment-response signature designed to enrich a Phase 2 study for patients more likely to benefit from CCL24 inhibition.
Future catalysts
- Initiation of a Phase 2 precision-medicine trial of nebokitug in rheumatoid arthritis in the first half of 2027.
- Topline results from the Phase 2 nebokitug rheumatoid arthritis trial in the first half of 2028.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Chemomab Therapeutics (CMMB)?
Chemomab Therapeutics (CMMB) most recently closed at 2.80 USD, a +5.66% move versus the previous session.
What is the market cap of Chemomab Therapeutics (CMMB)?
Chemomab Therapeutics currently has a market capitalization of 12.5M USD on BioPharmSignal.
What does Chemomab Therapeutics do?
Immune-Fibrotic Disease Company Chemomab Therapeutics is a clinical-stage biotechnology company developing therapies for diseases driven by fibrosis and inflammation. Its research is centered on CCL24, a soluble signaling protein implicated in immune-cell recruitment, tissue remodeling, and fibrotic disease progression. CCL24 Biology CCL24 is believed to...
On which exchange is CMMB stock listed?
Chemomab Therapeutics (CMMB) is associated with NASDAQ, Israel, Biopharma.
What is Immune-Fibrotic?
Immune-Fibrotic Disease Company Chemomab Therapeutics is a clinical-stage biotechnology company developing therapies for diseases driven by fibrosis and inflammation.
Which conditions is Chemomab Therapeutics targeting with Immune-Fibrotic?
Chemomab Therapeutics is associated with inflammatory disease based on its company overview and current catalyst commentary.
How does Chemomab Therapeutics describe recent progress with Immune-Fibrotic?
Initiation of a Phase 2 precision-medicine trial of nebokitug in rheumatoid arthritis in the first half of 2027. Topline results from the Phase 2 nebokitug rheumatoid arthritis trial in the first half of 2028.
What is Disease?
Immune-Fibrotic Disease Company Chemomab Therapeutics is a clinical-stage biotechnology company developing therapies for diseases driven by fibrosis and inflammation.